$12.48
0.12[0.97%]
Last update: 1:25PM Get Real Time Here
Nurix Therapeutics
(NASDAQ:NRIX)Latest News for Nurix Therapeutics Stock (NASDAQ:NRIX)
Nurix Therapeutics Stock (NASDAQ: NRIX)
Categories: All
Friday, April 12, 2024
- Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Apr 12, 2024, 2:47PM
- Nurix Therapeutics shares are trading lower after the company priced an upsized public offering of 10,166,667 shares of common stock at $15 per share.Benzinga Newsdesk - Apr 12, 2024, 9:23AM
- Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market SessionAvi Kapoor - Apr 12, 2024, 8:04AM
- Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 12, 2024, 5:32AM
- Nurix Therapeutics Prices Upsized $175M Public Offering Of 10,166,667 Common Shares At $15/ShareBenzinga Newsdesk - Apr 12, 2024, 2:50AM
Thursday, April 11, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Apr 11, 2024, 4:31PM
- Nurix Therapeutics shares are trading lower after the company announced that it commenced a $125 million underwritten public offering.Benzinga Newsdesk - Apr 11, 2024, 4:12PM
- Nurix Therapeutics Commences Public Offering Of $125M Of Its Common Stock And, In Lieu Of Common Stock, In Case Of Certain Investors, Pre-funded Warrants To Purchase SharesBenzinga Newsdesk - Apr 11, 2024, 4:01PM
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 11, 2024, 1:33PM
- RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $23Benzinga Newsdesk - Apr 11, 2024, 10:34AM
- Nurix Therapeutics shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $24 to $25.Benzinga Newsdesk - Apr 11, 2024, 10:17AM
- Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Apr 11, 2024, 10:01AM
- Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $25Benzinga Newsdesk - Apr 11, 2024, 6:45AM
- Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Apr 11, 2024, 4:38AM
Wednesday, April 10, 2024
Tuesday, April 09, 2024
- Nurix Therapeutics Reports First Clinical Evidence Of CNS Activity Of NX-5948, Orally Available, BTK Degrader In Development For B Cell MalignanciesBenzinga Newsdesk - Apr 9, 2024, 1:16PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Apr 9, 2024, 12:31PM
- Nurix Therapeutics shares are trading higher after the company announced an extension of its ongoing research program with Sanofi for STAT6.Benzinga Newsdesk - Apr 9, 2024, 11:51AM
- BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Apr 9, 2024, 10:43AM
- Nurix Therapeutics Extends Ongoing Research Program With Sanofi For STAT6; Anticipates Nominating A Clinical Candidate Within The First Year Of ExtensionBenzinga Newsdesk - Apr 9, 2024, 7:01AM
- Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Apr 9, 2024, 6:23AM
Tuesday, April 02, 2024
- Critical Insights From Nurix Therapeutics Analyst Ratings: What You Need To KnowBenzinga Insights - Apr 2, 2024, 1:00PM
- Needham Maintains Buy on Nurix Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Apr 2, 2024, 9:20AM
- Gilead Sciences Extends Research Term By Two Years For Nurix Therapeutics' Deal, Announced In 2019, For $15M Extension Fee; Nurix Eligible For $73.5M In Preclinical Research Milestones And Licensing Fees, And $1.7B In Sales/Development MilestoneBenzinga Newsdesk - Apr 2, 2024, 7:06AM
Wednesday, March 20, 2024
Monday, March 11, 2024
- Analyst Scoreboard: 7 Ratings For Nurix TherapeuticsBenzinga Insights - Mar 11, 2024, 1:01PM
- Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Mar 11, 2024, 10:18AM
- Nurix Therapeutics shares are trading higher after the company announced that the FDA lifted the partial clinical hold on NX-2127 Phase 1 trial.Benzinga Newsdesk - Mar 11, 2024, 8:00AM
- Nurix Therapeutics Says FDA Lifts Partial Clinical Hold On NX-2127 Phase 1 TrialBenzinga Newsdesk - Mar 11, 2024, 7:02AM
Monday, February 26, 2024
- Nurix Therapeutics shares are trading higher after Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $9 to $10.Benzinga Newsdesk - Feb 26, 2024, 11:38AM
- Morgan Stanley Maintains Equal-Weight on Nurix Therapeutics, Raises Price Target to $10Benzinga Newsdesk - Feb 26, 2024, 11:10AM
Tuesday, February 20, 2024
Friday, February 16, 2024
- Decoding 4 Analyst Evaluations For Nurix TherapeuticsBenzinga Insights - Feb 16, 2024, 3:01PM
- RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $22Benzinga Newsdesk - Feb 16, 2024, 12:38PM
- Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price TargetBenzinga Newsdesk - Feb 16, 2024, 5:39AM
Thursday, February 15, 2024
Friday, February 02, 2024
Thursday, February 01, 2024
Tuesday, January 16, 2024
Monday, January 08, 2024
Thursday, December 28, 2023
Monday, December 11, 2023
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Dec 11, 2023, 12:35PM
- Nurix Therapeutics Presents Clinical Data From Its Novel Bruton's Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual MeetingBenzinga Newsdesk - Dec 11, 2023, 12:02PM